Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.

ABSTRACT:

Background

There is currently limited literature addressing the reporting of alopecia in multiple sclerosis (MS) patients treated with disease-modifying therapies (DMTs). Anecdotal reports of hair thinning from patients on various DMTs prompted further investigation of a large database.

Objective

To analyze total reports, source of reporting, age distribution, and sex distribution of alopecia associated with DMTs.

Methods

FDA Adverse Event Reporting System (FAERS) public dashboard and OpenFDA database were analyzed for alopecia reports between January 1, 2009, and June 30, 2020, attributed to usage in MS of FDA approved DMTs. The main outcomes included total reports for each drug, age, sex distribution, and reporting source. OpenFDA data was used for statistical analy

SUBMITTER: Porwal MH 

PROVIDER: S-EPMC9234852 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature